[Federal Register Volume 84, Number 137 (Wednesday, July 17, 2019)]
[Notices]
[Page 34254]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-15245]


=======================================================================
-----------------------------------------------------------------------

U.S.-CHINA ECONOMIC AND SECURITY REVIEW COMMISSION


Notice of Open Public Hearing

AGENCY: U.S.-China Economic and Security Review Commission.

ACTION: Notice of open public hearing.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given of the following hearing of the U.S.-
China Economic and Security Review Commission.
    The Commission is mandated by Congress to investigate, assess, and 
report to Congress annually on ``the national security implications of 
the economic relationship between the United States and the People's 
Republic of China.'' Pursuant to this mandate, the Commission will hold 
a public hearing in Washington, DC on July 31, 2019 on ``Exploring the 
Growing U.S. Reliance on China's Biotech and Pharmaceutical Products.''

DATES: The hearing is scheduled for Wednesday, July 31, 2019 at 9:00 
a.m.

ADDRESSES: 428A Russell Senate Office Building, Washington, DC. A 
detailed agenda for the hearing will be posted on the Commission's 
website at www.uscc.gov. Also, please check the Commission's website 
for possible changes to the hearing schedule. Reservations are not 
required to attend the hearing.

FOR FURTHER INFORMATION CONTACT: Any member of the public seeking 
further information concerning the hearing should contact Leslie 
Tisdale Reagan, 444 North Capitol Street NW, Suite 602, Washington, DC 
20001; telephone: 202-624-1496, or via email at [email protected]. 
Reservations are not required to attend the hearing.

SUPPLEMENTARY INFORMATION:
    Background: This is the seventh public hearing the Commission will 
hold during its 2019 report cycle. The hearing will assess China's role 
in global health industries and implications for U.S. health, biotech, 
pharmaceutical firms, and the U.S. public. The hearing will also 
examine the activities of Chinese health and biotech firms in the 
United States and the ability of U.S. health and biotech firms to 
access the China market. The hearing will be co-chaired by Senator 
James Talent and Commissioner Michael Wessel. Any interested party may 
file a written statement by July 31, 2019 by mailing to the contact 
above. A portion of each panel will include a question and answer 
period between the Commissioners and the witnesses.
    Authority: Congress created the U.S.-China Economic and Security 
Review Commission in 2000 in the National Defense Authorization Act 
(Pub. L. 106-398), as amended by Division P of the Consolidated 
Appropriations Resolution, 2003 (Pub. L. 108-7), as amended by Public 
Law 109-108 (November 22, 2005), as amended by Public Law 113-291 
(December 19, 2014).

    Dated: July 12, 2019.
Daniel W. Peck,
Executive Director, U.S.-China Economic and Security Review Commission.
[FR Doc. 2019-15245 Filed 7-16-19; 8:45 am]
 BILLING CODE 1137-00-P